| ID | 57722 |
| JaLCDOI | |
| FullText URL | |
| Author |
Yokoyama, Akihiro
Division of Hematology, Department of Internal Medicine, NHO Tokyo Medical Center
Kada, Akiko
Department of Clinical Trials and Research, Clinical Research Center, NHO Nagoya Medical Center
Saito, Akiko M.
Department of Clinical Trials and Research, Clinical Research Center, NHO Nagoya Medical Center
Sawamura, Morio
Department of Hematology, NHO Shibukawa Medical Center
Komeno, Takuya
Department of Hematology, NHO Mito Medical Center
Sunami, Kazutaka
Department of Hematology, NHO Okayama Medical Center
Takezako, Naoki
Department of Hematology, Disaster Medical Center of Japan
|
| Abstract | Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexamethasone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed MM. Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1, 8, 15, and 22; oral lenalidomide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1, 8, 15, 22, 36, 43, 50, and 57 for 6 cycles. The primary endpoint was the overall response rate.
|
| Keywords | bortezomib
lenalidomide
dexamethasone
myeloma
|
| Amo Type | Clinical Study Protocol
|
| Publication Title |
Acta Medica Okayama
|
| Published Date | 2019-12
|
| Volume | volume73
|
| Issue | issue6
|
| Publisher | Okayama University Medical School
|
| Start Page | 547
|
| End Page | 552
|
| ISSN | 0386-300X
|
| NCID | AA00508441
|
| Content Type |
Journal Article
|
| language |
English
|
| Copyright Holders | CopyrightⒸ 2019 by Okayama University Medical School
|
| File Version | publisher
|
| Refereed |
True
|
| PubMed ID | |
| Web of Science KeyUT |
